Monique Thammavong, APRN
Family · van Buren, ARNPI 1275932253
Payments from drug & device makers
Across 245 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$526
- Amgen$360
- Biohaven Pharmaceutical Holding Company Ltd.$225
- Pfizer$151
- Novo Nordisk$126
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,013100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 110 | $1,184 |
| AstraZeneca | 25 | $526 |
| Amgen | 14 | $360 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $225 |
| Pfizer | 10 | $151 |
| Novo Nordisk | 7 | $126 |
| Lilly USA, LLC | 8 | $125 |
| Johnson & Johnson | 1 | $125 |
| Stryker | 1 | $121 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $106 |
| Vertex | 2 | $87 |
| Exact Sciences | 5 | $83 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Astellas Pharma US Inc | 4 | $75 |
| GSK | 5 | $74 |
| Phathom Pharmaceuticals, Inc. | 4 | $71 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $62 |
| Novartis | 3 | $57 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Abbott | 3 | $46 |
| Boehringer Ingelheim | 2 | $37 |
| Almatica Pharma LLC | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Halozyme Inc | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$125
- EVENITY$125
- XARELTO$125
- FlowTriever$121
How this compares
$4,013 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 38 | $43,425 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $43,387 |
| MounjaroTirzepatide | 27 | $27,541 |
| OzempicSemaglutide | 25 | $23,185 |
| FarxigaDapagliflozin Propanediol | 30 | $19,937 |
| XareltoRivaroxaban | 30 | $17,254 |
| LinzessLinaclotide | 19 | $13,164 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,870 |
| Spiriva HandihalerTiotropium Bromide | 12 | $12,807 |
| MyrbetriqMirabegron | 13 | $9,180 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $7,951 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $6,148 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $6,139 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,550 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 153 | $4,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $74 | $51,33876 claims |
| PfizerEliquis | $151 | $43,42538 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $526 | $38,35870 claims |
| Lilly USA, LLCMounjaro | $125 | $27,54127 claims |
| Novo NordiskOzempic | $126 | $23,18525 claims |
| Johnson & JohnsonXarelto | $125 | $17,25430 claims |
| AbbVieLinzess | $1,184 | $13,16419 claims |
| Astellas Pharma US IncMyrbetriq | $75 | $9,18013 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $25 | $6,95624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.
Other family in van Buren
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.